AR polyglutamine stretch-encoding (CAG) and polyglycine stretch-encoding (GGN) polymorphisms were shown to correlate with the individual symptoms of PFS in a cohort of 66 patients.

Two cases of PFS were reported, suffering progressive symptoms after finasteride withdrawal that included penile atrophy, post-orgasm weakness, ejaculatory dysfunction, osteomuscular and neuropsychiatric problems. One of the patient had taken only one dose.

fMRI findings in a cohort of post-finasteride patients without pre-existing depression revealed abnormal function in brain areas linked to sexual arousal and major depression.

A case report of PFS with multisystem involvement and without neuropsychological complaints following use of dutasteride and finasteride for hair loss.

79 post-finasteride patients were evaluated, finding physical, sexual and cognitive symptoms. Most had AMS scores indicating severe androgen deficiency. ASEX responses indicated sexual dysfunction not present before use. A trend of worsening after withdrawal was observed.

“Female PFS” was reported. Devastating long-term consequences for women represent a small but real subset of finasteride-related long term adverse outcomes.

Using datamining techniques on FAERS adverse event data, low-dose finasteride was associated with more reports than expected of serious sexual dysfunction in young men. Suicidal ideation was also disproportionally highly reported.

Meta-analysis of 34 clinical trials of Finasteride for hair loss discovered serious flaws, poor quality reporting and systematic bias​. None had adequate safety reporting.

24 PFS patients were assessed for serum androgens and spermatogenic deficits. 13% had low total testosterone. 13% had low serum DHT. 16% had severe oligospermia.

A significantly higher occurrence of “extreme length” androgen receptor polymorphisms was observed in 69 PFS patients as compared to controls.

Reporting the first significant molecular level evidence of differences in PFS patients, androgen receptor expression was significantly higher in prepuce cell lines compared with those from control subjects.

Persistent physical, sexual, psychological, and cognitive symptoms experienced by 131 PFS patients were characterised. Adverse effects persisting in each domain suggests a possible “Post-Finasteride Syndrome”.

In an expanded pilot study, altered levels of neuroactive steroids, associated with depressive symptoms, were present in PFS patients despite discontinuing finasteride treatment.

In a pilot study, altered levels of neuroactive steroids, associated with depressive symptoms, were present in PFS patients despite discontinuing finasteride treatment.

54 PFS patients were reassessed at a mean of 14 months following initial interview. Persistent sexual side effects continued to be present in 96%.

Depressive symptoms and suicidal thoughts were markedly more frequent in a group of 61 PFS patients than in a control group.

Persistent sexual dysfunction was characterised in 71 otherwise healthy men who had used finasteride for hair loss.

The possibility of a causal relationship between 5a-reductase inhibitor use and persistent sexual dysfunction in a subset of consumers was determined.